



AROA BIOSURGERY DECEMBER 2020 QUARTERLY WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'Aroa' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew today, Wednesday 27 January 2021 at 11am AEDT to discuss the December 2020 Appendix 4C and quarterly report.

Attend online: Investors and interested parties can register for the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_Oyp5TKWyQZyBn11zx4cJ2g

Investors are invited to submit questions prior to the webinar to shinsley@aroabio.com or do so via the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody', its products are developed from the Company's proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa's products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio.

Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX).
www.aroabio.com/

Contacts

Investor

Simon Hinsley
Investor Relations
shinsley@aroabio.com
+ 61 401 809 653

Media

Australia

Matthew Wright
matt@nwrcommunications.com.au
+61 451 896 420

New Zealand

Piet De Jong
piet.dejong@baldwinboyle.com
+64 21 812 766